A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
AXIM BIOTECHNOLOGIES, INC.
AXIM
$604K
Mkt Cap
$0.00
+0.00%
AXIM BIOTECHNOLOGIES, INC. (AXIM) has a 5-year average return on invested capital (ROIC) of -14.6%. This is below average and may indicate limited pricing power.
AXIM BIOTECHNOLOGIES, INC. (AXIM) has a market capitalization of $906K. It is classified as a small-cap stock.
AXIM BIOTECHNOLOGIES, INC. (AXIM) does not currently pay a regular dividend.
AXIM BIOTECHNOLOGIES, INC. (AXIM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AXIM BIOTECHNOLOGIES, INC. (AXIM) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
AXIM BIOTECHNOLOGIES, INC. (AXIM) reported earnings per share (EPS) of $-0.04 in its most recent fiscal year.
The Ledger Terminal provides 13 years of financial data for AXIM BIOTECHNOLOGIES, INC. (AXIM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Axim Biotechnologies, Inc., a Nevada corporation, is a leading developer of diagnostic healthcare solutions serving to enhance the health of people. Through the development of diagnostic solutions that quickly and accurately diagnose various diseases, our products allow healthcare workers to quickly test and treat at the point-of-care, which leads to improved patient outcomes and provides numerous economic benefits to the healthcare system. Axim’s core competencies include development of rapid lateral flow immunoassays, reagents and monoclonal antibody development for such assays. Our current products fall into these categories: (1) Eye Health, wherein we acquired two FDA cleared 510(k) tests for dye eye disease and have internally developed a third assay; and (2) SARS-CoV-2 neutralizing antibody tests Following the acquisition of two FDA cleared 510(k) tests for dye eye disease, the Company’s product focus has been primarily in the area of Eye Health.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 93K | - | - | - | 0 | - |
| Net Income | -4.1M | -8.1M | -6.2M | -16M | -6.4M | -6.4M |
| EPS | $-0.02 | $-0.04 | $-0.04 | $0.12 | $-0.06 | $-0.10 |
| Free Cash Flow | 0 | -1.0M | -2.1M | -2.5M | -3.3M | -5.0M |
| ROIC | -49.0% | -0.0% | -0.0% | -871.1% | -43.7% | -303.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -540,706.68 | -883,144.70 | -1.93 | 2.66 | -0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.3M | -2.8M | -4.7M | -14M | -4.9M | -6.5M |
| Operating Margin | -2490.3% | - | - | - | - | - |
| ROE | 0.0% | - | - | - | -409.4% | - |
| Shares Outstanding | 302M | 201M | 156M | 224M | 107M | 152M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 43K | 75K | 0 | N/A | N/A | N/A | N/A | N/A | 0 | N/A | N/A | N/A | 93K |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | 0 | 571K | 236K | 1.4M | 2.1M | 2.5M | 427K | 285K | 154K | 125K | 90K |
| SG&A | 10K | 4K | 506K | 9.5M | 3.4M | 1.8M | 3.2M | 4.3M | 4.5M | 5.7M | 4.1M | 2.2M | 1.9M |
| EBIT | N/A | N/A | -506K | -10M | -3.8M | -3.1M | -5.0M | -6.5M | -4.9M | -14M | -4.7M | -2.8M | -2.3M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2490.3% |
| Net Income | -15K | -89K | -583K | -10M | -7.3M | -4.2M | -6.8M | -6.4M | -6.4M | -16M | -6.2M | -8.1M | -4.1M |
| Net Margin | -34.4% | -119.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -4452.1% |
| Non-Recurring | 0 | 0 | 0 | 0 | 652K | 652K | 9K | 3K | 0 | 6.0M | 102K | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | N/A | N/A | -54.1% | N/M | N/M | -113.5% | -190.4% | N/M | -43.7% | N/M | -0.0% | -0.0% | -49.0% |
| ROE | -541.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -409.4% | N/A | N/A | N/A | 0.0% |
| ROA | -11.0% | -94.1% | -146.6% | -1009.2% | -537.5% | -228.9% | -315.5% | -381.1% | -98.6% | -301.2% | -148.2% | -193.4% | -110.9% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 25K | -33K | -339K | -1.5M | -1.3M | -3.1M | -4.8M | -5.0M | -3.2M | -2.5M | -2.0M | -1.0M | -759K |
| Free Cash Flow | -75K | -133K | -339K | -1.6M | -1.3M | -3.1M | -4.8M | -5.0M | -3.3M | -2.5M | -2.1M | -1.0M | 0 |
| Owner Earnings | 18K | -51K | -340K | -7.5M | -2.7M | -3.1M | -5.8M | -6.9M | -5.5M | -5.7M | -3.6M | -1.7M | -1.1M |
| CapEx | 100K | 100K | 0 | 17K | 0 | 0 | 0 | 0 | 97K | 40K | 9K | 0 | 0 |
| Maint. CapEx | 5K | 16K | 1K | 1K | 4K | 8K | 11K | 3K | 16K | 2.1M | 426K | 427K | 232K |
| Growth CapEx | 95K | 84K | N/A | 16K | N/A | N/A | N/A | N/A | 81K | 0 | 0 | N/A | 0 |
| D&A | 5K | 16K | 1K | 1K | 4K | 8K | 11K | 3K | 16K | 2.1M | 426K | 427K | 232K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2K | 2K | 0 | 6.0M | 1.4M | 56K | 911K | 1.8M | 2.3M | 1.1M | 1.1M | 198K | 92K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 2.0M | 8K | 0 | 0 | 1.2M | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 31K | 50K | 339K | 677K | 96K | 2.6M | -1.5M | -1.0M | 3.2M | 3.6M | 4.3T | 4.1T | 273K |
| Cash & Equiv. | 19K | 0 | 661K | 134K | 713K | 2.1M | 1.8M | 512K | 457K | 453K | 47K | 156K | 6K |
| Long-Term Debt | N/A | N/A | 0 | 400K | 46K | N/A | N/A | N/A | N/A | 4.0M | 4.3T | 4.1T | 94K |
| Debt/Equity | -10.64 | -0.53 | -1.72 | -0.48 | -0.34 | -0.74 | -0.07 | -0.00 | 2.66 | -1.93 | -883144.70 | -540706.68 | 0.00 |
| Interest Coverage | N/A | N/A | -15.6 | -232.5 | -13.6 | -10.0 | -11.0 | -26.2 | -21.1 | -56.4 | -2.7 | -2.7 | -2.7 |
| Equity | -5K | -94K | -581K | -1.7M | -2.4M | -6.3M | -6.1M | -6.8M | 1.6M | -2.3M | -4.8M | -7.7M | -9.5M |
| Total Assets | 133K | 57K | 738K | 1.3M | 1.4M | 2.2M | 2.1M | 1.7M | 11M | 5.3M | 4.2M | 4.1M | 3.7M |
| Total Liabilities | 138K | 151K | 1.3M | 3.0M | 3.8M | 8.5M | 8.2M | 8.5M | 9.7M | 7.7M | 9.0M | 12M | 13M |
| Intangibles | 94K | 54K | N/A | N/A | 63K | 63K | 54K | 51K | N/A | 4.4M | 4.0M | 3.6M | 3.4M |
| Retained Earnings | -20K | N/A | -692K | -11M | -18M | -22M | -29M | -35M | -42M | -58M | -64M | -72M | -75M |
| Working Capital | -98K | -148K | -581K | -1.4M | -1.6M | -5.6M | -1.3M | -1.8M | -783K | -1.9M | -3.3M | -5.8M | -6.6M |
| Current Assets | 39K | 3K | 738K | 1.2M | 1.4M | 2.1M | 2.0M | 1.6M | 713K | 637K | 104K | 156K | 20K |
| Current Liabilities | 138K | 151K | 1.3M | 2.5M | 3.0M | 7.7M | 3.3M | 3.4M | 1.5M | 2.6M | 3.4M | 6.0M | 6.6M |
| Per Share Data | |||||||||||||
| EPS | -0.00 | 0.00 | -0.02 | -0.27 | -0.17 | -0.08 | -0.12 | -0.10 | -0.06 | 0.12 | -0.04 | -0.04 | -0.02 |
| Owner EPS | 0.00 | -0.00 | -0.01 | -0.20 | -0.06 | -0.06 | -0.10 | -0.05 | -0.05 | -0.03 | -0.02 | -0.01 | -0.00 |
| Book Value | -0.00 | -0.00 | -0.02 | -0.05 | -0.06 | -0.12 | -0.11 | -0.04 | 0.01 | -0.01 | -0.03 | -0.04 | -0.03 |
| Cash Flow/Share | 0.00 | -0.00 | -0.01 | -0.04 | -0.03 | -0.06 | -0.09 | -0.03 | -0.03 | -0.01 | -0.01 | -0.01 | -0.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 33.0M | 33.0M | 29.1M | 37.4M | 42.9M | 52.1M | 56.3M | 152.0M | 106.8M | 223.6M | 156.1M | 201.5M | 302.0M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.3 | N/A | N/A | -0.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 34.1 | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 9.8 |
| FCF Yield | N/A | N/A | -0.1% | -6.9% | -0.4% | -0.7% | -9.7% | -20.5% | -6.2% | -4.0% | -47.0% | -25.6% | N/A |
| Market Cap | 0 | 0 | 291M | 22M | 354M | 465M | 50M | 25M | 53M | 63M | 4.4M | 4.0M | 906K |
| Avg. Price | 0.00 | 0.00 | 10.00 | 2.41 | 1.45 | 9.19 | 3.50 | 0.95 | 0.43 | 0.61 | 0.10 | 0.03 | 0.00 |
| Year-End Price | 0.00 | 0.00 | 10.00 | 0.60 | 8.27 | 8.92 | 0.89 | 0.38 | 0.50 | 0.28 | 0.03 | 0.02 | 0.00 |
AXIM BIOTECHNOLOGIES, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -8.8%.
AXIM BIOTECHNOLOGIES, INC. (AXIM) has a book value per share of $-0.04, based on its most recent annual SEC filing.